The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.
Mercer L, Abhishek A, Kavirayani A, Ahmed A, Davidson A, Foulkes A, Jones C, Nash C, Rose-Parfitt E, Dhillon E, Zabate G, Twohig H, De Vere H, Scott J, Reynolds J, Holmes J, Hartley K, Warrier K, Nowak K, Parsons K, Bechman K, Bray L, Adikari M, Wood N, Faithfull N, Gullick N, Saha P, Heaton R, Deepak S, Hider S, Khalid S, Said SS, Ryan S, Kyle S, Raghuvanshi S, Tan SY, Shivamurthy V, Galloway J.
Mercer L, et al. Among authors: foulkes a.
Rheumatol Adv Pract. 2024 Jul 12;8(3):rkae077. doi: 10.1093/rap/rkae077. eCollection 2024.
Rheumatol Adv Pract. 2024.
PMID: 39006537
Free PMC article.
Review.